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Inﬂ uenza subjects with an antiviral claim within one day pre- and one day post-index 
and/or an antibiotic claim within three days pre- and three days post-index were 
identiﬁ ed. Subjects with a secondary respiratory infection within the two week post-
index period were identiﬁ ed via ICD-9 codes. RESULTS: The study cohort included 
270,057 members with inﬂ uenza (51.8% male; mean age 31.6 years). Antibiotics were 
prescribed in 63,358 (23.5%) of subjects (42,374 [15.7%] received an antibiotic only; 
20,984 [7.8%] received both an antiviral and an antibiotic). The majority of subjects 
with inﬂ uenza (157,447 [58.3%]) did not receive an antiviral. Among subjects receiv-
ing antibiotic treatment, 98.9% did not have a follow-up coded respiratory bacterial 
infection within two weeks. The mean antibiotic costs were $66.15 and $42.71 for 
subjects with and without a secondary bacterial respiratory infection, respectively. 
Antibiotic usage in inﬂ uenza subjects without a secondary bacterial respiratory infec-
tion accounted for approximately $2.7M (2009 US$). CONCLUSIONS: Almost all 
subjects with inﬂ uenza receiving antibiotic treatment did not have a secondary bacte-
rial respiratory condition. The cost associated with the empiric prescribing of antibiot-
ics was considerable. Furthermore, over half the subjects with inﬂ uenza did not receive 
antiviral therapy. As our study only allowed for one case per subject the total cost 
associated with empiric antibiotic prescribing in subjects with inﬂ uenza is likely an 
underestimate.
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OBJECTIVES: Prescribers, payers and health care decision-makers operating in 
diverse health care settings are increasingly examining the value of innovative treat-
ments. The analysis aims at estimating the relative value of the two preferred ﬁ rst-line 
oral antiviral treatment options for chronic hepatitis B (CHB) according to the EASL 
guidelines: entecavir (ETV) and tenofovir (TDF) from a Spanish payer’s perspective. 
METHODS: Hepatitis B disease was simulated using a health-state transition model 
with disease-states deﬁ ned as mild disease (Ishak F0/F1), ﬁ brosis (F2–F4) and advanced 
ﬁ brosis/cirrhosis (>F4), and complicated disease-states (decompensated cirrhosis, 
hepatocellular carcinoma, liver transplant and death) based on available natural 
history data. The value of treatment-speciﬁ c attributes on disease progression/regres-
sion was estimated from clinical practice data in real world settings in terms of lifetime 
events and costs avoided. Treatment attributes included: additional testing require-
ments at treatment initiation and required renal function monitoring; adverse events 
per product labelling; reversal of ﬁ brosis; and treatment intensiﬁ cation in case of 
suboptimal viral suppression to avoid potential resistance. a 5-year treatment duration 
was assumed. Primary model output is the estimated cost avoided per-patient per day 
of treatment, associated with the clinical attributes of ETV compared to TDF in the 
treatment of nucleoside-naïve HBeAg-positive and -negative CHB patients. RESULTS: 
The daily cost of antiviral therapy for a CHB patient was estimated at c13.2 for ETV 
compared to c9.6 with TDF. Lifetime treatment cost avoided due to ETV’s clinical 
attributes was quantiﬁ ed at c3.6 [95% conﬁ dence: interval: 2, 5.2] per day of therapy. 
CONCLUSIONS: Estimating total treatment cost-avoidance associated with speciﬁ c 
clinical attributes is a novel approach in assessing the value of treatment options. ETV 
exhibits the characteristics of a favourable CHB treatment option, which directly 
translates into economic and therapeutic added value.
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BACKGROUND: Visceral leishmaniasis (VL) (“Kalazar”) is an important public 
health issue in Brazil. The guidelines of Brazilian Ministry of Health set up pentavalent 
antimony as the ﬁ rst line treatment, and amphotericin (deoxicolate and liposomal) as 
the second line treatment of VL. There are evidences that liposomal amphotericin (LA) 
and amphotericin deoxicolate (AD) present similiar efﬁ cacy, but LA has a better safety 
proﬁ le. Unfortunately, its price has been the principal barrier to its usage by public 
health system. OBJECTIVES: To evaluate the impact of differential pricing policy of 
LA in the Brazilian public health system. METHODS: The global amount spent on 
medicines from 2007 to 2009 by the Ministry of Health on the different types of 
treatment was retrieved from the Brazilian sanitary surveillance system. The following 
associated costs were also analyzed: hospital care and professional services; laborato-
rial tests (potassium, urea, creatinine and transaminases); and loss of working days 
(average daily income). This information allowed us to perform the cost analysis of 
the different therapeutic options. RESULTS: The differential pricing policy for LA 
implemented in 2008 allowed a cost reduction of 76.8% (from US$5.881 to US$590 
per treatment) enabling the Ministry of Health to double the number of patients 
treated with LA. The associated costs of hospitalization and loss of productivity by 
patients are higher with AD than with LA, but the total cost of LA treatment (medica-
tion + associated costs) is still 11.3% to 27% higher. CONCLUSIONS: In a societal 
perspective it was shown that a substantial price reduction of a safer drug enhanced 
its use and distribution by the Ministry of Health. It became also evident that the 
policy of differential pricing is an effective way to promote access to an efﬁ cient and 
safer treatment of VL, a disease that mainly affects the poor.
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OBJECTIVES: The primary aim of this study was to determine the possible impact 
of appropriate prescribing of antibiotics on treatment outcomes, days of patient 
hospitalization and costs related to antibiotic treatment. METHODS: Data from case 
notes of all inpatients on antibiotic treatment and all antibiotic prescriptions from 
outpatient departments were collected from June 15 to July 15, 2006 at 5 government 
and mission hospitals in Lesotho. All prescriptions were classiﬁ ed into categories of 
appropriateness based on their conformities to criteria developed from principles of 
antibiotic prescribing. Analyses were further conducted to determine the possible 
impact that appropriate prescribing may have on treatment outcomes, days of patient 
hospitalization and costs of antibiotic treatments. RESULTS: A total of 307 inpatients 
and 867 outpatient prescriptions were assessed. Total frequencies of prescribed anti-
biotics were 584 and 1073 for inpatients and outpatients respectively. For inpatients 
antibiotics were most often prescribed for skin and soft tissue (31.7%) and respiratory 
tract (28.9%) infections. Outpatients received most antibiotics for respiratory tract 
(42.0%) and skin and soft tissue infection (21.9%) respectively. Of the 307 inpatient 
prescriptions 41.6% were appropriately written for either empiric treatment or pro-
phylaxis of infections while 57.1% did not conform to antibiotic prescribing princi-
ples. a majority (81.0%) of outpatient prescriptions were in line with the prescribing 
principles. Inpatient antibiotic prescribing patterns based on principles of antibiotic 
prescribing have had a positive impact on treatment outcomes, days of hospitalization 
and costs of antibiotic treatment. In outpatients prescribing of antibiotics based on 
principles of antibiotic prescribing failed to show any signiﬁ cant impact on costs of 
antibiotics. Due to geographical challenges the outcome for treatment could not be 
determined for outpatients. CONCLUSIONS: Rational prescribing had a positive 
impact on treatment outcomes.
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OBJECTIVES: To assess cost-beneﬁ t and cost-effectiveness studies examining seasonal 
inﬂ uenza vaccination in the healthy, working-age population of the United States (US). 
METHODS: A systematic review of economic evaluations investigating the cost-
beneﬁ t or cost-effectiveness of vaccinating healthy adults was conducted on articles 
published between January 1990 and January 2010. Studies considered for inclusion 
in this review were identiﬁ ed using Medline, Embase, Econlit, and Google Scholar (n 
= 11). The source and appropriateness of parameters (epidemiological data, probabili-
ties, and costs), the designs employed, and the sufﬁ ciency of sensitivity analysis were 
considered during the review. RESULTS: Seven studies were identiﬁ ed as appropriate 
for this review. Key inputs of the selected studies included inﬂ uenza or ILI attack rates, 
outpatient visits averted, total vaccination costs, and lost workdays. All studies were 
conducted in the US and from the societal perspective; three were randomized, clinical 
trials and the remaining four constructed economic simulation models to compare 
vaccination to antivirals or no intervention. Results ranged from net savings of $69.19 
to net costs of $85.89 per vaccination (4 studies) and from $103.95 to $1004.85 per 
episode of inﬂ uenza averted (1 study). Only 2 studies reported cost-effectiveness ratios; 
these ranged from $6,930 to $50,510 per quality-adjusted life-year gained. Nearly all 
of the studies conducted sensitivity analysis; results were most sensitive to variation 
in wage rates, levels of worker productivity, the cost and effectiveness of vaccination, 
and the rate of illness. CONCLUSIONS: This systematic review found that seasonal 
inﬂ uenza vaccination of healthy, working-age adults is generally not cost saving, 
requiring an investment to generate health beneﬁ ts. The decision to vaccinate such a 
group will depend upon the societal and payer valuation of those beneﬁ ts.
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OBJECTIVES: Identifying budgetary implications and opportunities for earlier detec-
tion versus late detection of HIV (CD4 cell count less than 200/μl) in the 1 through 
5 year term following diagnosis. In 2009, there were 90,468 HIV positive individuals 
not accounting for unreported HIV positive cases (in 2008, estimated additional 24%). 
Late detection HIV patients account for 32% from the total. METHODS: A literature 
review was conducted using MEDLINE, Cochrane Library, EMBASE and CRD for 
guidelines and clinical trials published 1995–2010 in UK, England, Scotland, Wales, 
Northern Ireland, USA, Canada, Australia, Norway and EU-26. We extrapolated UK 
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population breakdown, survival rates, average costs of triple and quadruple HAART 
(Highly Active Antiretroviral Therapy) therapy, inpatient, outpatient care costs—HIV 
related HRG costs and excess cost ratio due to late presentation. Study follows stan-
dard good modeling practices by discounting, adjusting for survival, and considering 
multiple time horizons for analyses. UK data sources include: BHIVA, NHS, HPA and 
SOPHID. RESULTS: From 1995–2010 literature review yielded 126 publications 
related to late detection, of which 18 were included in our study design. The number 
of publications has rapidly increased over the last 12 months. Preliminary results 
suggest that 10% of HIV detection shift from late to early detection (2655 patients 
or 3.2% of Late HIV detection) would result in £20.3 million conservative savings 
just in the ﬁ rst year (keeping index multiplier scalar for HIV spread rate at zero). Over 
5-year term, such annual shift would result in 708.25 life-years saved or £14.2 million 
in additional savings. CONCLUSIONS: Enhanced testing to achieve earlier detection 
and initiation on HAART could potentially reduce overall costs of HIV medical care. 
Further research is required to determine additional budgetary implications of HIV 
comorbidity patterns.
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OBJECTIVES: Human papillomavirus (HPV) has been implicated as a causal factor 
in cervical cancer (CC), the second most common cancer among women worldwide. 
Prophylactic vaccination against HPV-16/18 has been shown to be highly effective in 
preventing HPV related infections and pre-cancerous lesions. The aim of this study 
was to determine the potential clinical and economic impact of combining CC screen-
ing programme with HPV vaccination programme with the bivalent HPV-16/18 
vaccine in women aged 25 (when CC screening starts) compared to screening alone. 
METHODS: A Markov cohort model was adapted to the Italian setting. The model 
replicates the HPV infection natural history leading to CC and includes the effect of 
screening and vaccination. Based on the latest results of the PATRICIA clinical trial 
for the bivalent vaccine, the vaccine efﬁ cacy includes cross-protection against non-
vaccine HPV types 31/33/35/39/45/51/52/56/58/59. The vaccine efﬁ cacy in naïve girls 
and HPV-exposed women (>17-years old) was differentiated. Lifetime protection and 
90% vaccination coverage were assumed. Costing was analyzed from the perspective 
of the Italian health care system. Main outcomes are lifetime costs, QALYs, CC cases, 
deaths and ICER. Both costs and effects were discounted at 3% annually to calculate 
the ICER. RESULTS: The model shows that, compared to screening alone, vaccinating 
a single cohort of 330,000 women aged 25 would prevent over a lifetime 696 CC 
cases and 316 CC deaths (undiscounted) of which 131 and 59 respectively are due to 
cross-protection, with a discounted ICER of c33,918 per QALY gained. The ICER 
remains under the cost-effective threshold deﬁ ned by the WHO (between 1 and 
3xGDP/capita). CONCLUSIONS: Under the assumptions of the model, extending 
vaccination to young adult women post-HPV exposure could lead to a substantial 
reduction in CC and remains cost-effective in Italy compared with screening alone. 
Cross-protection would play an important role in this reduction.
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OBJECTIVES: Rotavirus is the leading cause of severe gastroenteritis in children under 
5 years. Two vaccines are currently available: RotaTeq® (Merck/Sanoﬁ  Pasteur MSD) 
and Rotarix® (GSK). Published economic models on rotavirus vaccination have pro-
duced contradicting results. We reviewed and critically appraised existing economic 
models. METHODS: The literature search covered worldwide cost-effectiveness 
models of RotaTeq® and Rotarix® published or presented at conferences until 
October 2009. We extracted information on model structures, input data (epidemiol-
ogy, vaccine efﬁ cacy, utilities, vaccination costs) and results. RESULTS: We identiﬁ ed 
44 publications referring to distinct cost-effectiveness analyses.18 used cost per QALY 
as primary outcome, providing 22 incremental cost-utility ratios (ICURs) for high-
income countries. Thirteen ICURs came from health authorities and 9 from manufac-
turers. While some European studies predicted cost-savings from societal perspective, 
the ICUR was estimated at up c160,000 per QALY for the UK, from NHS perspective. 
5 of 13 analyses from health authorities reported ICURs below c30,000 per QALY 
gained, compared to 7 of 9 studies from manufacturers. There were many differences 
between models, such as perspective, epidemiological inputs, vaccine efﬁ cacy and 
vaccination costs. However differences in results were mainly driven by assumptions 
related to estimation of QALYs: utility values, duration of symptoms, inclusion of 
quality of life burden for caregivers and for cases without medical attention. CON-
CLUSIONS: Results of cost-effectiveness analyses are highly variable due to uncer-
tainty surrounding epidemiological inputs, and most importantly to assumptions for 
deriving QALYs. Different choices were attributable to different value judgments, and 
to the difﬁ culty of measuring and valuing quality of life in children, which lead to a 
situation where neither manufacturers nor health authorities obtained valid utilities. 
There is currently no valid reference case for cost-utility analyses in paediatrics. More 
open communication and expertise sharing between authorities and manufacturers 
could lead to more reliable analyses.
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OBJECTIVES: Streptococcus pneumonia is associated with two invasive diseases 
(meningitis and bacteremia) and non-invasive disease (pneumococcal pneumonia), 
which has caused high morbidity and mortality in infants and the elderly in Taiwan. 
a cost-effectiveness analysis of pneumococcal conjugate vaccine (PCV 10) in Taiwan 
was conducted using transmission-dynamic model. METHODS: As static pharmaco-
economic model fails to account for vaccination-induced herd-immunity, we devel-
oped an age-structured multi-compartment dynamic model to estimate both economic 
and clinical impact of universal PCV10 vaccination over 10-year time horizon under 
health care system’s perspective in Taiwan. Model parameters such as economic and 
clinical burden of pneumococcal diseases in Taiwanese population, vaccine efﬁ cacy, 
utilities and demographic parameters were captured by retrospective population-based 
National Health Insurance Reimbursement Database (NHIRD), published sources, 
unpublished data, and assumptions made in consultation with clinical experts. Uni-
variate sensitivity analyses were conducted to test the robustness of model parameters. 
RESULTS: Assuming a four-dose schedule and 90% of vaccination coverage for both 
vaccines, universal infant vaccination with PCV10 would prevent 133 cases of IPD, 
122,476 cases of pneumococcal pneumonia and 3,857 deaths, an equivalent of 93,393 
life-years and leads to a net medical cost savings of NT$ 6,047.4 million, compared 
to no vaccination. At the current proposed price of NT$2,700 for PCV10, the incre-
mental cost-effectiveness ratio (ICER) is expected to be cost-effective with NT$106,362 
(US$3,324) per life-year gained. The program’s cost-effectiveness results are highly 
sensitive to the vaccine price and number of doses while not sensitive to uncertainty 
in disease incidence and costs of treatment. CONCLUSIONS: Universal pediatric 
PCV10 vaccination in Taiwan is estimated to have considerable impact on reducing 
the burden of pneumococcal diseases and expected to be cost-effective in payer’s 
perspective compared to no vaccination.
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OBJECTIVES: To assess the efﬁ ciency of daptomycin as ﬁ rst-line therapy (D) versus 
daptomycin as rescue therapy after failure of vancomycin (V+D) or linezolid (L+D) in 
gram-positive bacteremia treatment. METHODS: A cost-effectiveness analysis com-
paring the three therapeutic alternatives (D, V+D and L+D) was performed using data 
from a previous observational study (EUCORE). In the present sub-study, data on 19 
(D), 33 (V+D) and 19 (L+D) bacteremic patients were analyzed. Effectiveness was 
measured in terms of cure or clinical improvement. Costs were gathered from “BOT” 
and “e-salud” Spanish databases. Direct costs (medication and hospitalization) due to 
bacteremia were included. Costs are expressed in 2009 Euros. Patients were observed 
until either end of daptomycin therapy or exitus. a probabilistic multivariate sensitivity 
analysis was carried out. Dispersion was estimated using bootstrap (three alternative 
scenarios were considered in the simulations: 50%, 25% and 10% of the estimated 
dispersion) and Monte Carlo simulations were performed for both costs (log-normally 
distributed) and effectiveness (normally distributed) measures. RESULTS: Effective-
ness ﬁ gures: D: 84.2% (95%CI: 60.4%–96.6%); V+D: 87.9% (95%CI: 71.8%–
96.6%); L+D: 68.4% (95% CI: 43.5%–87.4%); pvalue = 0.206 (Chi2). Average costs 
per treated patient: D: c6672.8 (95%CI: 4076.8–9268.8); V+D: c9786.6 (95%CI: 
7,124.7–12,448.5); L+D: c12,190.4 (95%CI: 8,693.2–15,687.7); pvalue < 0.001 
(Kruskal-Wallis). Cost-Effectiveness Incremental Ratios: c53,478.8 (D versus V+D) 
and −c6,639.5 (D versus L+D) per additional cured patient. Sensitivity analysis results: 
D versus V+D: D is efﬁ cient with lower costs (in 41.2%–77.9% of the simulations) 
and dominant (22.1%–38.0%); D versus L+D: D is dominant (44.6%–99.6%) and 
efﬁ cient with lower costs (0.4%–30.0%). CONCLUSIONS: Daptomycin as ﬁ rst-line 
therapy is mainly a dominant alternative when compared to daptomycin as rescue 
therapy after linezolid failure, showing better clinical results with lower associated 
costs. Daptomycin as ﬁ rst-line therapy does not show signiﬁ cant differences in effec-
tiveness when compared to daptomycin as rescue therapy after vancomycin failure, 
but it shows signiﬁ cantly lower costs.
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OBJECTIVES: Vaccination with the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) is the current standard in Germany for diagnosis deﬁ ned risk groups (age 
5–59 years) and for seniors (≥60 years). a redeﬁ nition of this recommendation 
